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Abstract
Oseltamivir (TamifluH) is the most widely used drug against influenza infections and is extensively stockpiled worldwide as
part of pandemic preparedness plans. However, resistance is a growing problem and in 2008–2009, seasonal human
influenza A/H1N1 virus strains in most parts of the world carried the mutation H274Y in the neuraminidase gene which
causes resistance to the drug. The active metabolite of oseltamivir, oseltamivir carboxylate (OC), is poorly degraded in
sewage treatment plants and surface water and has been detected in aquatic environments where the natural influenza
reservoir, dabbling ducks, can be exposed to the substance. To assess if resistance can develop under these circumstances,
we infected mallards with influenza A/H1N1 virus and exposed the birds to 80 ng/L, 1 mg/L and 80 mg/L of OC through their
sole water source. By sequencing the neuraminidase gene from fecal samples, we found that H274Y occurred at 1 mg/L of
OC and rapidly dominated the viral population at 80 mg/L. IC50 for OC was increased from 2–4 nM in wild-type viruses to
400–700 nM in H274Y mutants as measured by a neuraminidase inhibition assay. This is consistent with the decrease in
sensitivity to OC that has been noted among human clinical isolates carrying H274Y. Environmental OC levels have been
measured to 58–293 ng/L during seasonal outbreaks and are expected to reach mg/L-levels during pandemics. Thus,
resistance could be induced in influenza viruses circulating among wild ducks. As influenza viruses can cross species
barriers, oseltamivir resistance could spread to human-adapted strains with pandemic potential disabling oseltamivir, a
cornerstone in pandemic preparedness planning. We propose surveillance in wild birds as a measure to understand the
resistance situation in nature and to monitor it over time. Strategies to lower environmental levels of OC include improved
sewage treatment and, more importantly, a prudent use of antivirals.
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Introduction
The recent A/H1N1 pandemic has once again put the spotlight
on influenza as a major human health problem. In a pandemic
situation, preparedness plans rely heavily on vaccines and antiviral
drugs. Vaccines are effective as prophylaxis, but the process of
mass-scale production takes several months and therefore antiviral
drugs are essential, especially during the first wave of a pandemic.
A major and growing concern is the development of resistance
to the few antiviral drugs available. Of these drugs, Oseltamivir
(TamifluH) is most widely used. Resistance to oseltamivir was very
rarely detected in clinical practice until the 2007–08 season when
the mutation H274Y in the neuraminidase (NA) gene occurred.
The H274Y mutation confers resistance to oseltamivir and was
found in circulating seasonal H1N1 virus, initially in Europe [1]
but the proportion of seasonal H1N1 carrying H274Y quickly
increased and predominated worldwide in the 2008–09 season [2].
Oseltamivir usage did not correlate with the occurrence of
resistant virus [2,3], implying that the strain containing H274Y
had a fitness comparable to other circulating viruses. After the A/
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e24742H1N1 pandemic, this seasonal H1N1 virus has virtually disap-
peared from the strains circulating among humans. To avoid
confusion, the virus is therefore denoted as ‘‘former seasonal
H1N1’’. The H274Y mutation has also emerged in patients with
pandemic A/H1N1 influenza treated with oseltamivir [4,5]. So far,
the H274Y mutant is rare among pandemic A/H1N1 virus but
could increase as some cases of suspected human-to-human trans-
missionhave beenreported [6].Fitnessstudiesofresistantpandemic
A/H1N1 have shown equivalent virulence in animal models [7,8]
but signs of decreased transmissibility in ferrets [7].
Oseltamivir is extensively stockpiled; e.g. the US had 40 million
treatment courses in stock as of April 2009 [9]. Worldwide, more
than 220 million courses have been stockpiled, and the shelf
life has been extended to 7 years [10]. The active metabolite of
oseltamivir, oseltamivir carboxylate (OC), is poorly absorbed from
the gastrointestinal tract and the drug is therefore administered as
a prodrug, oseltamivir phosphate (OP). OP is readily absorbed and
rapidly converted to OC by esterases, and more than 75% of an
oral dose reaches the circulation as OC. The active metabolite is
then excreted in an unchanged form via the urine [11]. OC is
stable in the aqueous phase and degrades poorly in sewage treat-
ment plants (STPs) and surface water [12,13]. Thus, there is
reason to believe that OC is present in the aquatic environment
near STPs when oseltamivir is used extensively. Japan has had the
highest per-capita consumption of oseltamivir during several
seasonal influenza outbreaks. For example, during the 2004/2005
season more than 10 million treatment courses were used,
corresponding to almost 10% of the population [14]. Two studies
have detected OC in surface water and outgoing water from STPs
in Japan during seasonal influenza outbreaks [15,16].
Dabbling ducks are the natural reservoir for influenza A viruses
[17] and can be exposed to OC in the aquatic environment near
STPs. An infection with influenza A virus in ducks results in mild
clinical signs. Physiological data from an infection experiment
showed only a transient, small increase in body temperature [18]
and in another experiment mallard hens had a transient decrease
in egg production [19]. Migrating dabbling ducks positive for
influenza A had a 20 g lower mean weight than uninfected birds
[20]. The infection of low-pathogenic avian influenza viruses in
dabbling ducks is mainly gastrointestinal [21]. OC is poorly
absorbed from the bowel in humans and it is likely that the
absorption is poor also in ducks. However, the gastrointestinal
location of the infection in dabbling ducks means that OC could
directly affect replicating virus in the intestine.
If resistance is established in influenza viruses circulating
among wild birds, there is a risk of re-entry to humans, either
via direct transmission or reassortment — this is further com-
mented on in Discussion. Figure 1 displays a summary of the
general hypothesis.
We hypothesized that influenza virus in mallards (Anasplatyrhynchos)
exposed to low levels of OC can develop resistance. Therefore, we
infected mallard ducks with an avian influenza A/H1N1 virus
isolated from a wild mallard and experimentally varied OC levels in
the sole water source. Uninfected ducks were then successively
introduced and the virus was transmitted seriallyfromducktoduckto
mimic the passing of influenza between ducks in the wild. Resistance
development was assessed by sequencing the NA gene from daily
fecal samples. Three experiments were performed at 80 ng/L, 1 mg/
La n d8 0mg/L of OC. Our results demonstrate that resistance
develops through acquisition of the mutation H274Y.
Figure 1. Summary of the general hypothesis. As OC is poorly degraded in STPs and surface water, it can enter aquatic environments where
dabbling ducks can be exposed to the substance. Dabbling ducks are the natural influenza reservoir and have a perpetual circulation of influenza
viruses in their population. Thus, there is a risk of resistance development in the bowel of the ducks where replicating virus and OC co-exist. Through
reassortment or direct transmission, an oseltamivir-resistant influenza virus could spread to humans. Illustration by S.J. Ja ¨rhult.
doi:10.1371/journal.pone.0024742.g001
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Mallard Model
Real-time reverse transcriptase PCR (q-PCR) on fecal samples
confirmed that all ducks were negative for influenza A when
transferred to the experiment room and that all ducks were
infected with the A/H1N1 strain during the experiment. Viral
shedding started day 1 post infection (pi) in most ducks and
reached a maximum at day 2–3 pi. All ducks shed virus for 5 days.
The 4 ducks at 80 mg/L of OC that were in the experiment for 7
days also shed virus intermittently day 6–7 pi. There was no
difference in shedding pattern between ducks primarily infected
with the viral stock solution and those where the infection was
secondarily transmitted from another duck. Virus was detectable
in the water samples from most days (69/73 evaluable samples) but
in lower concentrations compared to the fecal samples.
OC Analysis
Average concentrations of OC in the water from the sole water
source of the ducks were measured at 83 ng/L 623%, 0.95 mg/L
624% and 81 mg/L 611% (mean value and relative standard
deviation) in the respective experiment. OC levels in the water
were similar when measured immediately after addition of OC
and before discarding the same water one day later (tested for
three days during each experiment).
OC Resistance
In the 80 ng/L experiment H274Y was not detected in any of
the 134 evaluable samples. However, in the 1 mg/L experiment, 2
of 127 samples contained a mixture of genotypes consisting of both
wild-type and H274Y strains (Figure 2). Those samples were from
days 8 and 23 after the start of the experiment (second and seventh
duck generation). The occurrence of both genotypes was con-
firmed by re-sequencing the samples twice, including a new RNA
extraction from the original fecal sample. In the 80 mg/L
experiment, sequencing of fecal samples showed H274Y 2 days
pi and from 3 days pi and onwards, only H274Y was present in all
21 samples.
The 50% inhibitory concentration (IC50) of 13 tested wild-type
viruses from the experiment was 2–4 nM whereas the IC50 of 15
tested H274Y isolates was 400–700 nM. Two different isolations
of the same sample with mixed genotypes resulted in either the
wild-type or the H274Y sequence with a corresponding IC50 (see
Figure 3). The A/Mallard/Sweden/51833/2006(H1N1) strain
used for inoculation had an IC50 of 3 nM.
Analysis of Sequences from NCBI
See Table 1.
Discussion
In an experimental set-up, we demonstrated that oseltamivir
resistance develops through the acquisition of H274Y when
mallards infected with influenza A/H1N1 virus were exposed to
1 mg/L of OC, and that the H274Y mutation rapidly dominated
the viral population at an OC concentration of 80 mg/L. Previous
reports of environmental OC levels during seasonal influenza
outbreaks in Japan range from 58–293 ng/L [15,16]. In a
Figure 2. Genotypic results of experiments with 80 ng/L, 1 mg/L and 80 mg/L of OC. Sequencing results of the NA gene at amino-acid
residue 274 (N2 numbering). Blue = cytosine (C), green = adenine (A) and red = thymine (T), corresponding to uracil (U) in the RNA sequence. Wild-
type genotype = CAC = histidine, H274Y = TAC = tyrosine.
doi:10.1371/journal.pone.0024742.g002
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reaching the same magnitude as the levels where resistance
development was observed in this study.
Oseltamivir resistance was confirmed functionally by an enzyme
activity (MUNANA) assay. The more than hundred-fold higher
IC50 among H274Y positive isolates is consistent with data from
human clinical isolates [22]. Isolation of a sample with mixed
genotypes can result either in a wild-type or in a H274Y-positive
virus, which demonstrates that either genotype can dominate the
replication during the isolation process. As there is no drug
pressure when virus replicates in hen eggs, this indicates that the
viral fitness is not dramatically different in the H274Y mutant
compared to the wild-type virus.
The global spread of former seasonal H1N1 viruses carrying
H274Y has shown that virus with this mutation can outcompete
wild-type virus without drug pressure [2]. It has recently been
demonstrated that this is probably due to ‘‘permissive’’ compen-
satory mutations e.g. R222Q and V234M, that restore the
decreased surface expression of NA caused by H274Y [23]. By
analogy, H274Y acquired in wild ducks during a temporary
increase in environmental levels of OC could prevail even when
oseltamivir is no longer widely used. As dabbling ducks are the
natural reservoir for influenza A viruses [17], the circulating viral
gene pool is large and variable. An example of the variable avian
gene pool is a study where the sensitivity to OC in avian A/H1N1
viruses showed a much larger variation as compared to mammalian
viruses [24]. As one of the few circulating former seasonal human
A/H1N1 strains could adapt to H274Y it seems likely that some of
the many circulating avian strains have the right genetic makeup to
harborH274Ywithoutlosingviral fitness.Compared to a randomly
selected former seasonal A/H1N1 strain containing H274Y (A/
Norway/1736/2007), the A/H1N1 strain used in this study had a
protein homology of 84%. When compared to a wild-type pan-
demic A/H1N1 strain (A/Georgia/NHRC0001/2011), the protein
homology was higher (90%) indicating a closer similarity. This is
consistent with the fact that the pandemic A/H1N1 virus was
derived fromswinevirusesthat havea recent avianorigin[25]while
the former seasonal A/H1N1 virus has been circulating among
humans for many years. The studied A/H1N1 strain did not
contain R222Q or V234M. Thus, there is a lower probability that
H274Y would be sustained without drug pressure if the virus does
not contain other mutations increasing the surface expression of NA
[23]. However, the A/H1N1 strain used in this study contained the
mutation R222N. Although R222N is not previously described as a
permissive mutation, Q and N have very similar uncharged polar
side chains, suggesting that this mutation could have permissive
capacities. H274Y emergence under drug pressure has been
observed both in early treatment studies of former seasonal A/
H1N1 with oseltamivir [26] and in pandemic A/H1N1 [4,5].
Therefore,it is not surprising that H274Y emerges inthe studied A/
H1N1 strain although established permissive mutations are missing.
Little is known about the resistance situation for influenza A
viruses in nature. The few H274Y-positive sequences found when
screening the NCBI database (Table 1) indicate that the mutation
is not yet common in nature. The two NA sequences from the
H5N1 viruses isolated from swans in Aztrakhan, Russia, 2005 are
identical in sequence, either being two submissions of the same
virus or two samples from different birds carrying the same virus.
Thus, the four H5N1 viruses positive for H274 probably represent
three different viruses. The other two H274Y-positive H5N1
viruses are from a mute swan (Cygnus olor) in the Caspian Sea from
2006 and a chicken in Hong Kong from 2002. Interestingly, an
H274Y-positive H1N1 virus was recently published in NCBI (22
nd
December 2010) and it has not yet been commented on in a
journal article. This virus was obtained from a 2007 sample of a
duck in Minto Flats in Interior Alaska, a habitat with high densities
of nesting ducks. Thus, H274Y-positive avian N1 viruses can be fit
enough to occur in the wild, both in highly pathogenic H5N1 and
in low-pathogenic H1N1 viruses without obvious drug pressure.
Furthermore, it has recently been demonstrated by our group that
resistance mutations to neuraminidase inhibitors occur also among
influenza viruses isolated from wild birds in Sweden [27]. These
viruses were obtained from dabbling ducks in an environment
where no OC is present. Taken together, these observations
demonstrate that H274Y can exist among influenza viruses in wild
birds also when OC is absent. Thus, there is a possibility of
resistance accumulation when oseltamivir is widely used, even if
OC disappears from the environment in between influenza
outbreaks. We therefore propose surveillance in wild bird
populations as an important measure to gain more knowledge of
the resistance situation in nature and to monitor it over time.
The in vivo mallard model described here provides a promising
means to study viral evolution under dynamic conditions, e.g. drug
Figure 3. Different results of two isolations of a sample with
mixed genotype. The mixed-genotype sample from day 23 pi in the
1 mg/L OC experiment was isolated twice in embryonated hen eggs.
One of the isolations yielded a wild-type virus and one an H274Y
mutant with corresponding IC50-values.
doi:10.1371/journal.pone.0024742.g003
Table 1. Wild-type and H274Y-containing avian influenza A
viruses of N1 subtype in the NCBI database.
H274Y Wild-type Total
H1N1 1 208 209
H5N1 4 (3)* 2132 2136 (2135)
(other H)N1 0 459 459
Total 5 (4) 2799 2804 (2803)
* indicates that the four H274Y-positive H5N1 viruses probably represent three
distinctly different viruses, see Discussion.
doi:10.1371/journal.pone.0024742.t001
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the virus is subjected to both replication and transmission as in the
natural situation. The similar shedding patterns in ducks primarily
infected by inoculation and secondarily infected by transmission
and the finding that all ducks introduced were infected
demonstrated that the natural route of transmission used in the
model is effective also in an experimental setting. The timing of the
introduction of new birds at day 3 pi seems logical as ducks shed
the highest levels of virus day 2 and 3 pi. Considering the low
levels used, the water concentrations of OC were constant and
there were no signs of OC degradation during the one-day use of
each OC/water mixture. This is consistent with the fact that OC is
poorly degraded in surface water [12,13]. Possible future uses of
the mallard model, apart from drug exposure studies, include
persistence analysis of resistant viruses and in vivo testing of viruses
isolated from wild birds.
Strategies to reduce environmental levels of OC include
improved sewage treatment—some bioremeditative effect has
been shown by a granular bioplastic formulation of the fungus
Phanerochaete shrysosporium [28]. Furthermore, two bacterial strains
growing on OC as the sole carbon source has been isolated from
the sediment of Japanese rivers [12] and ozonization to lower OC
levels has been discussed [15]. However, to substantially reduce
the amount of OC in the environment, a prudent use of antivirals
is vital. In critically ill or immunosuppressed patients there is
growing evidence that a combination therapy approach can be
favorable in preventing resistance development in the treated
patient [29,30]. However, these patients constitute a small
minority and by restricting other uses in non-pandemic periods,
we can save the antivirals until needed.
Influenza A viruses can cross species barriers either by direct
transmission or by genetic reassortment with other influenza
viruses. An alarming scenario of direct transmission is if a high-
pathogenic avian influenza virus (e.g. H5N1) acquires the H274Y
mutation and then adapts to humans. By reassortment, an avian
influenza virus with an NA gene containing H274Y could combine
with human and other mammalian influenza viruses resulting in
an oseltamivir-resistant pandemic strain. Viruses from all four
influenza pandemics during the last century contain avian genetic
material [25]. Regardless of whether the route is by direct
transmission or by reassortment, the H274Y or other resistance
mutations can spread from birds to humans, thus disabling
oseltamivir, a cornerstone in pandemic preparedness planning.
In conclusion, our work demonstrates a hitherto unknown
setting for resistance development in influenza A. Environmental
levels of the active metabolite of the antiviral oseltamivir can
induce acquisition of the resistance mutation H274Y in influenza
A/H1N1 virus in mallards. There is a risk that H274Y, or other
resistance mutations, will be spread among the plethora of influenza
A viruses circulating in nature, including those with pandemic
potential. As oseltamivir is stockpiled worldwide as a cornerstone in
pandemic preparedness plans, the threat of an oseltamivir-resistant
influenza pandemic has major implications in a general public
health perspective.
Materials and Methods
Animals and Housing
This study was carried out in strict accordance with recom-
mendations from the Swedish Board of Agriculture. The protocol
was approved by the Ethical Committee on Animal Experiments
in Uppsala (permit C82/09). All efforts were made to minimize
suffering for the animals. Male mallard ducks were purchased
from a Swedish farm at the age of 3–6 months and then kept at the
National Veterinary Institute (Uppsala, Sweden). All mallards
initially tested negative for influenza A using q-PCR (described
below, [31]) and serology using a nucleoprotein-targeting ELISA
assay (Avian Influenza A Blocking ELISA, Pourquier, France).
Virus Preparation
The A/Mallard/Sweden/51833/2006(H1N1) strain (GenBank
accession number JF710317) was isolated from a wild mallard
sampled at Ottenby, Sweden. Virus isolation was performed by
inoculating 200 ml of the sample medium in the allantoic cavity of
10-day-old embryonated hen eggs. The allantoic fluid was
harvested three days later, centrifuged and virus growth was
confirmed by a standard hemagglutination test. Virus stock for
duck inoculation was obtained by a second passage, where diluted
allantoic fluid from the primary isolation was inoculated and
grown in the same fashion. The viral titer was determined by 50%
Embryo Infectious Dose (EID50) [32]. The NA gene of the virus
stock was sequenced in the same way as experimental samples (see
below) and no known markers of resistance were observed. The
NA sequence was used as a reference to monitor NA changes
during the experiment.
Experimental Set-up
Primary infection was performed by esophageal inoculation of
1 ml of viral stock solution corresponding to 10
8 EID50. Prior to
the experiment, the ducks were kept in a separate room. A 1 m
2
pool was the sole water source in the experiment room. The water
was changed daily and OC was added; the final concentrations in
the different experiments were measured at 80 ng/L, 1 mg/l and
80 mg/L, respectively. The 80 ng/L and 1 mg/L experiments
consisted of ten duck generations, each lasting five days (see
Figure 4). New ducks were introduced every third day and kept
together for two days before the preceding generation was
removed. In the 80 mg/ml experiment, two seven-day generations
were used. Each generation consisted of two ducks. To minimize
the risk of the next generation being infected by remaining virus
instead of the intended direct transmission, the room was
thoroughly cleaned before the introduction of a new generation.
Sampling and Virus Detection
When daily sampling was performed, ducks were put into
separate clean cardboard boxes. Fecal samples were obtained
either by cloacal swabbing or by swabbing of fresh feces from the
boxes. The samples were put in 1 ml of transport medium as
described earlier [33] and stored at 280uC. The water samples for
virus detection and OC analyses were taken daily and were stored
at 280uC and 220uC respectively.
Q-PCR
A previously published one-step real-time reverse transcriptase
PCR [31] targeting the matrix gene was used to monitor the
infection on a daily basis. The reaction was performed in a Corbett
Research Rotor-Gene 2000 Real-time ThermoCycler (Corbett
Research, Mortlake, Australia), using iScript one-step RT-PCR kit
for probes (Bio-Rad, Hercules, USA). A total reaction volume of
25 ml was used, containing 12.5 ml 2x RT-PCR reaction mix for
probes, 2.5 ml of RNA extract and final concentrations of 125 nM
of the probe, 0.5 ml of iScript reverse transcriptase and 200 nM of
each forward and reverse primer.
Sequencing
134 sequences of H1N1 NA retrieved from GenBank were used
for multiple sequence alignment using BioEdit V7.0.9.0 [34].
Milieu TamifluH Induces Resistant Influenza A/H1N1
PLoS ONE | www.plosone.org 5 September 2011 | Volume 6 | Issue 9 | e24742Three pairs of primers were designed to cover the full-length
NA gene as shown in table 2. All primers were purchased from
Thermo Hybaid, Interactiva Division (Ulm, Germany).
RNA was isolated using the Magnatrix 8000 extraction robot
(Magnetic Biosolutions, Sweden) and Vet Viral NA kit (NorDiag
ASA, Oslo, Norway). PCR amplification of the NA gene was
performed using SuperScript III One-Step RT-PCR System with
Platinum Taq High Fidelity (Invitrogen) with primers 1 and 2. The
total reaction volume of 25 ml contained 12,5 ml of 2x reaction
buffer, 0,5 ml of Platinum Taq High Fidelity enzyme, 5 ml of RNA
extract and forward and reverse primers to a final concentration of
200 nM each. Some samples required an additional NA PCR with
a doubled reaction volume. The NA PCR-products were either gel
purified (Qiaquick PCR purification kit; Qiagen) or purified using
ExoSAP-IT treatment (Affymetrix). The purified PCR products
were sent to Macrogen, Korea, for sequencing. Sequences were
analyzed using SeqScape software (Applied Biosystems).
NA Inhibition Assay (NAIA)
Selected samples were grown in embryonated hen eggs, as
described in Virus Preparation. NA enzymatic activity was then
measured using the fluorogenic substrate 29-(4-methylumbelliferyl)-
a-D-N-acetylneuraminic acid (MUNANA; Sigma) [35]. The
fluorescence of the released 4-methylumbelliferone was measured
using a GloMax multiplate reader (Promega) at excitation and
emission wavelengths of 350 and 450 nm, respectively. For NAIA,
viral suspensions were adjusted to equivalent NA contents in MES
buffer (32.5 mM morpholineethanesulfonic acid, pH 6.5, 120 mM
NaCl, 4 mM CaCl2), based on preliminary determinations of the
NA activities in serial dilutions of the viral stocks. OC (RO0640802-
002;lot:01007B243804)wasobtainedfromRoche(F.Hoffmann-La
Roche Ltd, Basel, Switzerland). Viral suspensions were preincubat-
ed in the presence of various concentrations of OC (0.015 to
4000 nM) for one hour at 37uC in 96-well plates, with shaking.
Following the addition of substrate at a final concentration of
100 mM, the viruses were incubated for one hour at 37uC, and the
reaction was stopped by adding one volume of a solution of 1 M
glycine, pH 10.7, and 25% ethanol. Fluorescence values were
measured, and the IC50 for NA enzymatic activity was determined
from the dose-response curve, using GraphPad Prism Version 5
software (GraphPad software). IC50 values stated are means of
duplicate experiments.
OC Analysis
Two different arrangements of liquid chromatography-tandem
mass-spectrometry (LC-MS/MS) were used to analyze pre-filtered
(0.45 mm filters) water samples (0.5–10 ml; sample volumes were
adjusted to the exposure levels in the experiment) collected during
the three experiments. Water samples collected during the 80 ng/L
experiment were analyzed using an on-line LC/LC-tandem mass-
spectrometry (MS/MS) system including a PAL HTC autosampler
(CTC Analytics AG, Zwingen, Switzerland), a Surveyor LC-Pump
(Thermo Fisher Scientific, San Jose, CA, USA) connected to a
extraction Hypersil GOLD column (20 mm62.1 mm i.d.612 mm
particles, Thermo Fisher Scientific, Waltham, MA, USA) and an
Accela LC pump (Thermo Fisher Scientific, San Jose, CA, USA)
connected to an analytical Hypersil GOLD aQ column (50 mm
62.1 mm i.d.63 mm particles, Thermo Fisher Scientific, San Jose,
CA, USA) with a guard column (2 mm 62m m i . d .63 mm
Figure 4. Experimental set-up. Set-up for 80 ng/L and 1 mg/L experiments shown with blue blocks, 80 mg/L with red dotted lines.
doi:10.1371/journal.pone.0024742.g004
Table 2. Primers designed for PCR amplification and
sequencing of the neuraminidase (NA) gene.
Primer no. Sequence (59-3 9)
1 GCAGGAGTTCAAAATGAATCCAAATC
2 TGTTCAAAAAACTCCTTGTTTCTACT
3 CCATTGGGTCAATCTGTATGGTGA
4 GTTGCCATTCACCATTGACAAGTAGT
5 CTCATGCTCCCACTTGGAAT
6 GTGTCCTCTAACGGGGCATA
doi:10.1371/journal.pone.0024742.t002
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column) coupled to a triple stage quadrupole MS/MS TSQ
Quantum Ultra EMR (Thermo Fisher Scientific, San Jose, CA,
USA). The water samples collected during the 1 mg/L and 80 mg/L
experiments were analyzed by direct injection onto the analytical
Hypersil GOLD aQ column using the conventional LC-MS/MS
part of the system described above. In both analyses, heated
electrospray (HESI) in positive ion mode was used for ionization of
OC and two SRM transitions were monitored (285R138, collision
energy 20 V; 285R120, collision energy 30 V). The level of OC in
the samples was quantified using internal standard method (isotopic
labeled OC obtained from Roche, F. Hoffmann-La Roche Ltd,
Basel, Switzerland, was used as internal standard) with five
calibration points. The maximum difference between results at
quantification (285R138) and qualification (285R120) mass
transition was set to 20% as criterion for positive identification.
Analysis of NA Sequences from NCBI
On Jan 27, 2011, the NCBI Influenza Virus Sequence Database
[36] was screened for all avian influenza viruses of the N1 subtype.
Sequences were aligned using Muscle software [37] and viewed in
BioEDIT version 7.0.9.0.
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